Transcript Slide 1
Personalized Medicine in California
Kathryn Lowell,
Deputy Secretary for Life Sciences and Health Systems
February, 2009
CALIFORNIA BIOTECHNOLOGY
STATISTICS
In 2004, Governor Schwarzenegger championed and California voters
passed Proposition 71, devoting an unprecedented $3 billion to stem cell
research creating the California Institute of Regenerative Medicine (CIRM).
To date, the CIRM Governing Board has approved grants totaling more
than $693 million, making CIRM the largest source of funding for embryonic
and stem cell research in the world.
According to the National Science Foundation, six of the best-funded
research universities in the nation are in California, five of which are
University of California (UC) institutions. Also, one in four U.S. biotech
companies are located within 35 miles of a UC campus.
Potential of Personalized
Medicine
Application of genomic data to better target the delivery
of medical interventions - tailoring prescriptions to
defined sub-populations and possibly individuals
Crucial tool in the discovery and clinical testing of new
products that improve health care, personal health and
lower costs
Application of sophisticated, clinically useful diagnostic
tools that may help determine a patient’s predisposition
to a particular disease or condition
PERSONALIZED MEDICINE-FEDERAL
LEGISLATIVE LANGUAGE
The establishment of the Genomics and Personalized Medicine
Interagency Working Group.
Expanded & accelerated research programs to collect genetic &
genomic data.
A national biobanking research initiative.
Improved outreach to educate the public about molecular genetic
screening, diagnostics, & treatments.
Workforce development in genetics and genomics.
Improving the safety, efficacy, oversight, regulation of genetic tests.
PERSONALIZED MEDICINE: STATE
PERSPECTIVES
BTH as the economic development agency
with mission of promoting regional
growth and innovation
Interested in how to lower the State’s
health care costs -- as a purchaser
Interest in improving health outcomes
Validating the Economic
Potential of Personalized Medicine
Recent Deloitte report, “The ROI for Targeted Therapies: A Strategic
Perspective” examined:
Whether personalized medicine has a quantifiable ROI
Whether an economic framework be derived from case studies
that will demonstrate differences in ROI across industry
stakeholders
Report concluded that:
All stakeholder groups experienced a positive ROI under certain
conditions, with payers received marginal benefit after six years
Consumers stood to gain the most significant ROI opportunity
within the shortest time period
CALIFORNIA IS A LEADER IN
PERSONALIZED MEDICINE
Innovation in California
UCSF's Center for Translational and Policy Research
QB3 -- The California Institute for Quantitative
Biosciences (QB3), a cooperative effort among three
campuses of the University of California and private
industry, harnesses the quantitative sciences to
integrate our understanding of biological systems at all
levels of complexity - from atoms and protein molecules
to cells, tissues, organs and the entire organism.
Kathryn Lowell,
Deputy Secretary for Life Sciences and Health
Systems
[email protected]